Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monitoring of the immune responses following mogamulizumab containing treatment in patients with adult T-cell leukemia-lymphoma (MIMOGA study)

Trial Profile

Monitoring of the immune responses following mogamulizumab containing treatment in patients with adult T-cell leukemia-lymphoma (MIMOGA study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2019

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Pharmacodynamics
  • Acronyms MIMOGA
  • Most Recent Events

    • 24 Apr 2019 Results demonstrating the presence of skin-directed autoantibodies after mogamulizumab treatment published in the Clinical Cancer Research.
    • 30 Sep 2018 Planned End Date changed from 31 Jul 2015 to 31 Jul 2020.
    • 05 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top